Efficacy of hepatitis B vaccination in patients awaiting liver transplantation in prophylaxis of de novo HBV-infection of a graft
Abstract
Aim of investigation. To estimate the efficacy of vaccination against hepatitis B in patients in the Waiting list for liver transplantation, in prophylaxis of de novo infection of a graft.
Material and methods. Results of vaccination against hepatitis B in 41 patients with liver cirrhosis included into the Waiting list for orthotopic liver transplantation (OLT), and dynamics of HBV seromarkers in 72 patients before and after liver transplantation were analyzed.
Results. Only in 9 (22%) of the patients vaccinated against hepatitis B, the level of anti-HBs to the moment of OLT was over 100 mMU/ml. At one third of patients who had no signs of HBV-infection in past history before operation, anti-HBc have been revealed after OLT. In half of them de novo graft HBV-infection developed. Presence of anti-HBs in blood serum of recipients prevented infection even if anti-HBc appeared after OLT.
Conclusion. Vaccination against hepatitis B of patients with liver cirrhosis, etiologically not related to HBV-infection, standard doses of vaccine under the accelerated mode in most of the cases does not provide effective and sustained immunodefence and does not prevent development of graft HBV-infection de novo.
About the Authors
V. Ye. Syutkin
НИИ скорой помощи им. Н.В. Склифосовского
Russian Federation
Russian Federation
O. I. Andreytseva
НИИ скорой помощи им. Н.В. Склифосовского
Russian Federation
Russian Federation
A. A. Saliyenko
НИИ скорой помощи им. Н.В. Склифосовского
Russian Federation
Russian Federation
A. V. Chzhao
НИИ скорой помощи им. Н.В. Склифосовского
Russian Federation
Russian Federation
References
1. Barcena R., Moraleda G., Moreno J. et al. Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers // World J. Gastroenterol. – 2006. – Vol. 12, N 13. – P. 2070–2074.
2. Dickson R.C., Everhart J.E., Lake J.R. et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database // Gastroenterology. – 1997. – Vol. 113, N 5. – P. 1668–1674.
3. Douglas D.D., Rakela J., Wright T.L. et al. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient // Liver Transplant. – 1997. – Vol. 3, N 2. – P. 105–111.
4. Engler S.H., Sauer P.W., Golling M. et al. Immunogenicity of two accelerated hepatitis B vaccination protocols in liver transplant candidates // Eur. J. Gastroenterol. Hepatol. – 2001. – Vol. 13, N 4. – P. 363–367.
5. Fabia R., Levy M.F., Crippin J. et al. De novo hepatitis B infection after liver transplantation: sources of disease, incidence and impact // Liver Transplant. – 1998. – Vol. 4, N 1. – P. 119–127.
6. Horlander J.C., Boyle N., Manam R. et al. Vaccination against hepatitis B in patients with chronic liver disease awaiting liver transplantation // Am. J. Med. Sci. – 1999. – Vol. 318, N 5. – P. 304–307.
7. Idilman R., Colantoni A., De Maria N. et al. Impaired antibody response rates after high dose short interval hepatitis B virus vaccination of immunosuppressed individuals // Hepatogastroenterology. – 2003. – Vol. 50, N 49. – P. 217–221.
8. Kallinowski B., Benz C., Bucholz L. et al. Accelerated schedule of hepatitis B vaccination in liver transplant candidates // Transplant. Proc. – 1998. – Vol. 30, N 3. – P. 797–799
9. Mattos A.A., Gomes E.B., Tovo C.V. et al. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus // Gastroenterology. – 2004. – Vol. 41, N 3. – P. 180–184
10. Pascasio J.M., Aoufi S., Gash A. Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation // Transplant. Proc. – 2008. – Vol. 40, N 9. – P. 2943–2945
11. Prieto M., Gomez M., Berenguer M. et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody–positive donors in an area with high prevalence of anti-HBc positivity in the donor population // Liver Transplant. – 2001. – Vol. 7, N 1. – P. 51–58.
12. Roche B., Samuel D., Gigou M. et al. De novo and apparent de novo hepatitis B virus infection after liver transplantation // J. Hepatol. – 1997. – Vol. 26, N 3. – P. 517–526.
13. Roque-Afonso A.M., Feray C., Samuel D. et al. Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors // Gut. – 2002. – Vol. 50, N 1. – P. 95–99.
14. Su W.J., Ho M.C., Ni Y.H. et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection // J. Pediatr. Gastroenterol. Nutr. – 2009. – Vol. 48, N 2. – P. 203–208.
Review
For citations:
Syutkin V.Ye., Andreytseva O.I., Saliyenko A.A., Chzhao A.V. Efficacy of hepatitis B vaccination in patients awaiting liver transplantation in prophylaxis of de novo HBV-infection of a graft. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2010;20(2):20-24. (In Russ.)
Views:
61
Email this article 
